ABSTRACT
Objectives To develop a mathematical model to characterize age-specific case-fatality rates (CFR) of COVID-19.
Materials and Method Based on two large-scale Chinese and Italian CFR data, a logistic model was derived to provide quantitative insight on the dynamics between CFR and age.
Results and Discussion We inferred that CFR increased faster in Italy than in China, as well as in females over males. In addition, while CFR increased with age, the rate of growth eventually slowed down, with a predicted theoretical upper limit for males (32%), females (21%), and the general population (23%).
Conclusion Our logistic model provided quantitative insight on the dynamics of CFR.
Lay Summary Recently published studies have qualitatively shown that the COVID-19 case-fatality rates increased with age, with elder people at higher risk of fatality than younger ones. In our study, we presented a quantitative mathematical modeling approach to re-analyze those published data. Specifically, we were able to derive a logistic model to characterize age-specific CFRs. The derived mathematical model uncovered novel quantitative insights on the dynamics between CFR and age. Specifically, we inferred from the model that while CFR increased with age, the rate of growth eventually slowed down, with a predicted theoretical upper limit of 23% for the general population.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No external funding was received
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Not applied. We analyzed published datasets.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
We used published datasets that were referenced in our manuscript.
